ClinConnect ClinConnect Logo
Search / Trial NCT00710411

Inflammatory Response After Muscle and Skeleton Trauma

Launched by UNIVERSITY OF ULM · Jul 2, 2008

Trial Information

Current as of August 11, 2025

Completed

Keywords

Humans Patients Polytrauma Complement Inflammation Inflammatory Response Biomarkers Cytokines Cell Surface Markers Apoptosis Nf Kappa B Functional Polymorphisms Mesenchymal Stem Cell Severity Of Injury Iss Infections Systemic Inflammatory Response Syndrome Sirs Sepsis Severe Sepsis Shock Organ Dysfunctions Sofa Severity Of Disease Apacheii Sapsii Spaps3 Length Of Stay Wound Healing Outcome Mortality

ClinConnect Summary

Polytraumatized patients are via a systemic inflammatory response syndrome at high risk for an uneventful outcome in the posttraumatic phase. One of the main functions of the inflammatory response is the recognition and elimination of damaged tissues and microorganisms. In polytraumatized patients, a huge amount of damaged cells occurs which has to be eliminated by programmed cell death (apoptosis)without damaging surrounding tissues. It remains unclear whether, when and how an interplay of complement system, NF-kB, danger and pattern recognition receptors, apoptosis, mesenchymal stem cells...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • multiple trauma injury, injury severity score (ISS) \> 18 with
  • 1. isolated fractures of the extremities
  • 2. fractures of the extremities combined with blunt/penetrating visceral trauma
  • 3. fractures of the extremities combined with blunt/penetrating thoracic trauma
  • 4. isolated head injury with morphological changes in CCT
  • 5. combination of points 1 - 4
  • Exclusion Criteria:
  • life expectancy \< 24 hours
  • participation in other trials
  • ISS \< 18
  • cardiopulmonary reanimation on the accident scene or dying immediately after hospital admission
  • age \< 18 years
  • known or suspected pregnancy
  • patients with ray-treatment or chemotherapy within the last three months

About University Of Ulm

The University of Ulm is a leading academic institution located in Germany, renowned for its commitment to cutting-edge research and innovation in the fields of medicine and health sciences. As a clinical trial sponsor, the university leverages its robust network of researchers and clinical experts to advance medical knowledge and improve patient outcomes. With a focus on interdisciplinary collaboration, the University of Ulm conducts comprehensive clinical studies that adhere to the highest ethical standards and regulatory guidelines. Through its research initiatives, the university aims to contribute significantly to the development of new therapies and treatment modalities, fostering a deeper understanding of various health conditions.

Locations

Ulm, , Germany

Patients applied

0 patients applied

Trial Officials

Manfred M Weiss, MD, MBA

Principal Investigator

Clinic of Anesthesiology, University Hospital Medical School, Steinhoevelstrasse 9, 89070 Ulm, Germany

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials